Literature DB >> 15955739

mTOR--beyond transplantation.

Deborah A Young1, Cheryl L Nickerson-Nutter.   

Abstract

mTOR kinase plays a central role in the activation of many cell types, and blocking mTOR function with rapamycin results in arrest of the cell cycle at the G1 phase. Recently, several additional molecules have been identified in the mTOR pathway, providing further opportunities to interfere with cell activation and develop novel therapeutic agents. Under certain conditions and in specific cell types, activation can occur independently of mTOR and in the presence of rapamycin. Selective inhibition of cell activation in the appropriate setting might prove to be beneficial for several autoimmune or inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15955739     DOI: 10.1016/j.coph.2005.03.004

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  15 in total

Review 1.  Aging and TOR: interwoven in the fabric of life.

Authors:  Zelton Dave Sharp
Journal:  Cell Mol Life Sci       Date:  2010-10-21       Impact factor: 9.261

Review 2.  Aging and cancer: can mTOR inhibitors kill two birds with one drug?

Authors:  Zelton Dave Sharp; Arlan Richardson
Journal:  Target Oncol       Date:  2011-03-11       Impact factor: 4.493

Review 3.  Mammalian target of rapamycin: a central node of complex signaling cascades.

Authors:  Yoh Dobashi; Yasutaka Watanabe; Chihiro Miwa; Sakae Suzuki; Shinichiro Koyama
Journal:  Int J Clin Exp Pathol       Date:  2011-06-14

Review 4.  Metabolic pathways in T cell fate and function.

Authors:  Valerie A Gerriets; Jeffrey C Rathmell
Journal:  Trends Immunol       Date:  2012-02-17       Impact factor: 16.687

5.  Association of sirolimus with pericardial effusion in renal transplant patient and discussion of potential mechanism.

Authors:  Lingbin Meng; Bo Deng; Baoqiong Liu; Dwayne Gordon
Journal:  BMJ Case Rep       Date:  2019-07-15

Review 6.  Regulation and function of mTOR signalling in T cell fate decisions.

Authors:  Hongbo Chi
Journal:  Nat Rev Immunol       Date:  2012-04-20       Impact factor: 53.106

7.  Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study.

Authors:  Tien-I Karleen Su; Dinesh Khanna; Daniel E Furst; Gabriel Danovitch; Christina Burger; Paul Maranian; Philip J Clements
Journal:  Arthritis Rheum       Date:  2009-12

8.  Rapamycin Does Not Impede Survival or Induction of Antibody Responses to Primary and Heterosubtypic Influenza Infections in Mice.

Authors:  Justine S Liepkalns; Aseem Pandey; Amelia R Hofstetter; Amrita Kumar; Enitra N Jones; Weiping Cao; Feng Liu; Min Z Levine; Suryaprakash Sambhara; Shivaprakash Gangappa
Journal:  Viral Immunol       Date:  2016-07-22       Impact factor: 2.257

Review 9.  Modulation of adaptive immunity with Toll-like receptors.

Authors:  Santhakumar Manicassamy; Bali Pulendran
Journal:  Semin Immunol       Date:  2009-06-06       Impact factor: 11.130

10.  Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway.

Authors:  Weiping Cao; Santhakumar Manicassamy; Hua Tang; Sudhir Pai Kasturi; Ali Pirani; Niren Murthy; Bali Pulendran
Journal:  Nat Immunol       Date:  2008-08-31       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.